Table 6.
Multiple logistic regression exploring the association between taking ivermectin thrice, twice, or once, and >50% seizure reduction during M9 to M12 of follow-up (combined analysis for group 1 and group 2).
| Variables | OR | 95% CI | p-Value | |
|---|---|---|---|---|
| Ivermectin dose twice vs once | 4.469 | 1.250 | 16.620 | 0.026 |
| Ivermectin dose thrice vs once | 2.693 | 1.077 | 6.998 | 0.042 |
| Female vs male | 1.049 | 0.544 | 2.024 | 0.890 |
| Age | 1.006 | 0.970 | 1.045 | 0.759 |
| Weight (in kg) | 0.991 | 0.956 | 1.027 | 0.631 |
| Seizure frequency at baseline | 1.445 | 0.915 | 2.355 | 0.134 |
| Duration of epilepsy (years) | 1.087 | 0.744 | 1.590 | 0.675 |
| Microfilarial density at baseline * | 0.857 | 0.720 | 1.016 | 0.087 |
| Optimal vs sub-optimal AED adherence during last four months | 1.431 | 0.734 | 2.799 | 0.305 |
| >30 mg of AED increase (between M0 and M12) vs no increase | 0.250 | 0.122 | 0.496 | <0.001 |
| Study group 1 vs group 2 | 1.634 | 0.609 | 4.454 | 0.344 |
OR: Odds ratio; CI: Confidence interval; AED: Antiepileptic drug; *: Log-transformed.